Biological material pre-fixation treatment

• US 5,843,181 A
• Filed: 01/17/1997
• Issued: 12/01/1998
• Est. Priority Date: 04/18/1994
• Status: Expired due to Fees

• Current Assignee: Hancock Jaffe Laboratories, Inc.
• Original Assignee: Hancock Jaffe Laboratories, Inc.
• Inventors: Jaffe, Norman, Hancock, Warren D.
• Primary Examiner(s): Willse, David H.
• Application Number:
  US08/786,395
• Time in Patent Office: 683 Days
• Field of Search: 623/2, 623/900, 623/11, 8/94.11
• US Class Current: 128/898
• CPC Class Codes: A61L 2430/20 for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3645 Connective tissue
• CPC Class Codes: A61L 27/3683 subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/3691 characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device
• CPC Class Codes: Y10S 623/915 Method or apparatus for preparing biological material

Abstract

Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12° C. to 30° C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.

Claims

1. A method of making a bioprosthetic heart valve comprising the steps of:

exposing biological material comprising cellular and non-cellular structural components to at least one buffered solution having a pH in the range from about 5.0 to about 8.0 and a temperature in the range from about 12°

C. to about 30°

C. for a sufficient period of time to facilitate the degradation of said cells by autolytic enzymes within said cells, whereby at least one region of biological material is rendered substantially acellular while preserving the overall structural integrity and non-cellular structural components of the biological material, wherein the exposure occurs prior to any fixation of the biological material;

fixing the biological material; and

fabricating the bioprosthetic heart valve from the biological material by the addition of non-biological material.

2. The method of claim 1, wherein the biological material is derived from at least one animal selected from the group consisting of a bovine, a porcine, an ovine, a Macropodidae, a nonhuman primate, a human and a combination of any of the foregoing.

3. The method of claim 1, wherein the biological material is derived from a porcine.

4. The method of claim 1, wherein the biological material is at least one material selected from the group consisting of diaphragm, pericardium, heart valve, umbilical cord, artery, vein, fascia lata, dura mater, tendon, ligament, tympanic membrane, a fragment of any of the foregoing and a combination of any of the foregoing.

5. The method of claim 1, wherein the biological material is at least one material selected from the group consisting of a heart valve, a fragment of a heart valve and a combination of the foregoing.

6. The method of claim 1, wherein the biological material is a leaflet of a heart valve.

7. The method of claim 1, wherein the noncellular structural components include at least one structural component selected from the group consisting of collagen, elastin, laminin, teninsin, actinin, proteoglycans, a fragment of any of the foregoing and a combination of any of the foregoing.

8. The method of claim 1, wherein the buffered solution is at least one solution selected from the group consisting of sodium phosphate monobasic buffer, sodium phosphate dibasic buffers, phosphate citrate buffer and a combination of any of the foregoing.

9. The method of claim 8, wherein the buffered solution is a combination of sodium phosphate monobasic and dibasic buffers.

10. The method of claim 1, wherein the pH range is from about 6.0 to about 8.0.

11. The method of claim 10, wherein the pH range is from about 7.2 to about 7.6.

12. The method of claim 1, wherein the temperature range is from about 19°

C. to about 23°

C.

13. The method of claim 1, wherein the period of time is from about 24 hours to about 100 hours.

14. The method of claim 1, wherein the period of time is from about 65 hours to about 75 hours.

15. The method of claim 1, wherein the bioprosthetic heart valve comprises at least one leaflet formed, at least in part, of the biological material, wherein the at least one leaflet is adapted for reciprocal motion from an open position to a closed position upon blood flow through the valve.

16. The method of claim 15, wherein the bioprosthetic heart valve additionally comprises a generally tubular stent having an inflow end and an outflow end, and wherein the at least one leaflet is positioned in relation to the stent such that the reciprocal motion of the at least one leaflet occurs as blood flows from the inflow end of the stent through the outflow end of the stent.

17. The method of claim 16 wherein the stent has a generally circular cross-section.

18. The method of claim 16, wherein the stent has an inner surface and an outer surface and wherein the at least one leaflet is attached to the inner surface.

19. The method of claim 16, wherein the stent comprises non-biological material.

20. The method of claim 16 wherein the stent is adapted to permit blood flow therethrough.

21. The method of claim 15, wherein the at least one region of the biological material that is rendered substantially acellular is substantially all of the leaflet.

22. A method of making a bioprosthetic heart valve comprising the steps of:

performing controlled autolysis on biological material comprising cellular and non-cellular structural components, said controlled autolysis consisting essentially of exposing said biological material to at least one solution consisting essentially of a buffer having a pH in the range from about 5.0 to about 8.0 and a temperature in the range from about 12°

C. to about 30°

C. for a sufficient period of time to facilitate the degradation of said cells by autolytic enzymes within said cells whereby at least one region of the biological material is rendered substantially acellular while preserving the overall structural integrity and non-cellular structural components of the biological material, wherein the exposure occurs prior to any fixation of the biological material; and

fabricating the bioprosthetic heart valve from the biological material by the addition of non-biological material.

23. The method of claim 22 further comprising fixing said biological material.

24. The method of claim 22, wherein the biological material is derived from at least one animal selected from the group consisting of a bovine, a porcine, an ovine, a Macropodidae, a nonhuman primate, a human and a combination of any of the foregoing.

25. The method of claim 22, wherein the biological material is at least one material selected from the group consisting of diaphragm, pericardium, heart valve, umbilical cord, artery, vein, fascia lata, dura mater, tendon, ligament, tympanic membrane, a fragment of any of the foregoing and a combination of any of the foregoing.

26. The method of claim 22, wherein the noncellular structural components include at least one structural component selected from the group consisting of collagen, elastin, laminin, teninsin, actinin, proteoglycans, a fragment of any of the foregoing and a combination of any of the foregoing.

27. The method of claim 22, wherein the buffered solution is at least one solution selected from the group consisting of sodium phosphate monobasic buffer, sodium phosphate dibasic buffers, phosphate citrate buffer and a combination of any of the foregoing.

28. The method of claim 22, wherein the bioprosthetic heart valve comprises at least one leaflet formed, at least in part, of the biological material, wherein the at least one leaflet is adapted for reciprocal motion from an open position to a closed position upon blood flow through the valve.

29. The method of claim 28, wherein the bioprosthetic heart valve additionally comprises a generally tubular stent having an inflow end and an outflow end, and wherein the at least one leaflet is positioned in relation to the stent such that the reciprocal motion of the at least one leaflet occurs as blood flows from the inflow end of the stent through the outflow end of the stent.

30. The method of claim 29, wherein the stent has an inner surface and an outer surface and wherein the at least one leaflet is attached to the inner surface.

31. The method of claim 29, wherein the stent comprises non-biological material.

32. The method of claim 28, wherein the at least one region of the biological material that is rendered substantially acellular is substantially all of the leaflet.